mTOR inhibitor

Everolimus - Temsirolimus - Temsirolimus      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

advanced breast cancer (metastatic)

everolimus
BOLERO-2, 2011        NCTeverolimus + exemestaneexemestane alone HER-2 negative HR positive nsNAI failure previously treated with endocrine therapy Low risk of bias conclusive-11%-57%
TAMRAD , 2012      NCTeverolimus + tamoxifentamoxifen alone 1st line HER-2 negative HR positive postmenopausal previously treated with endocrine therapy Risk of bias suggesting-55%
BOLERO-3, 2014      NCTeverolimus + trastuzumab + vinorelbinetrastuzumab + vinorelbine alone HER-2 positive previously treated by taxanes trastuzumab failure Low risk of bias conclusive-22%
temsirolimus
HORIZON, 2013      NCTtemsirolimus + letrozoleletrozole alone 1st line HR positive postmenopausal Low risk of bias negative-11%-10%

renal-cell carcinoma (advanced)

everolimus
RECORD-1, 2008      NCTeverolimusplacebosuggesting-17%-70%
RECORD 3, 2014      NCTeverolimussunitinib - 40%
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007      NCTtemsirolimusinterferon alphasuggesting-27%
INTORSECT, 2014      NCTtemsirolimussorafenibnegative 31%-13%